Home > Boards > US Listed > Biotechs > Exact Sciences (EXAS)

The Exact Sciences team delivered another strong quarter

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 407
Posts 54,574
Boards Moderated 40
Alias Born 12/16/01
160x600 placeholder
Exact Sciences schedules annual meeting, second quarter 2020 earnings call PR Newswire (US) - 7/8/2020 6:00:00 AM
Annual Report of Employee Stock Plans (11-k) Edgar (US Regulatory) - 6/30/2020 9:19:00 AM
Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfav... PR Newswire (US) - 6/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) Edgar (US Regulatory) - 6/2/2020 6:08:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2020 6:01:05 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 6/1/2020 4:11:07 PM
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020 PR Newswire (US) - 5/29/2020 8:00:00 AM
Exact Sciences to participate in June investor conferences PR Newswire (US) - 5/26/2020 6:00:00 AM
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results PR Newswire (US) - 5/14/2020 6:00:00 AM
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results PR Newswire (US) - 5/14/2020 6:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/6/2020 4:11:26 PM
Exact Sciences Announces First Quarter 2020 Results PR Newswire (US) - 5/6/2020 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2020 4:04:20 PM
New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates ... PR Newswire (US) - 5/5/2020 10:30:00 AM
Exact Sciences to participate in May investor conference PR Newswire (US) - 5/4/2020 6:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2020 4:11:47 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/29/2020 4:10:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/24/2020 4:51:53 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/24/2020 4:48:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/24/2020 8:13:15 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2020 4:19:39 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/22/2020 4:15:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2020 4:33:30 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/17/2020 4:30:30 PM
Exact Sciences schedules first-quarter 2020 earnings call PR Newswire (US) - 4/8/2020 6:00:00 AM
TREND1 Member Level  Tuesday, 11/14/17 01:03:29 PM
Re: None
Post # of 609 
The Exact Sciences team delivered another strong quarter with $73 million in revenue, 161,000 completed Cologuard tests and more than 10,000 new ordering physicians and other healthcare providers. The growth and enthusiasm of our patient and physician customer bases are helping us begin to achieve our goal of making Cologuard the standard of care in colon cancer screening.

Third quarter cash use totaled $21.7 million. Adjusting for the MDxHealth payment in the second quarter, cash use improved by $7.1 million on better-than-expected operating results and some working capital benefits. We ended the quarter with cash and marketable securities of $462.5 million.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist